Loading
Researchers pioneer new method to generate non-embryonic stem cells
Researchers pioneer new method to generate non-embryonic stem cells

.- In what one expert calls a “major paper,” researchers have reported new advances in creating efficient and safe alternatives to human embryonic stem cells.

A team led by Derrick J. Rossi of the Children’s Hospital Boston used laboratory-made versions of natural biological signals to quickly convert ordinary skin cells into cells that appear virtually identical to embryonic stem cells. They can then coax these cells to change into specific tissues that would be a match for transplantation into patients, the Washington Post reports.

Douglas A. Melton, co-director of the Harvard Stem Cell Institute, said the research produced a “major paper” in the field of regenerative medicine.

Previous research pioneered in 2006 involved the creation of induced pluripotent stem (iPS) cells by activating four genes. However, the process involved inserting genes into cells using retroviruses, which raised the risk the cells could cause cancer.

The new approach involves the use of messenger RNA (mRNA). According to the Washington Post, the DNA inside cells use mRNA to create proteins needed to perform various vital functions. The researchers created mRNA molecules carrying instructions to tell the cell’s machinery to produce the four key proteins needed to reprogram the cell into an iPS cell.

The researchers found their method to be surprisingly fast and efficient at reprogramming the cells. The cells were converted in about 17 days, about half the time of previous methods. In other aspects the method proved up to 100 times more efficient than previous approaches.

Tests indicated the cells had not experienced any disturbance to the DNA and were virtually identical to embryonic stem cells. The researchers successfully coaxed the cells to become muscle cells.

Embryonic stem cell research (ESCR) is controversial because it involves the use of cells harvested by killing human embryos. Its opponents include pro-life ethicists and Catholic bishops.

According to the Washington Post, Rossi and other researchers said ESCR is still crucial because the embryonic stem cells validate alternatives.

The legality of federal funding for embryonic stem cell research is currently being contested in court.


Ads by AdsLiveMedia(What's this?)

* The number of messages that can be online is limited. CNA reserves the right to edit messages for content and tone. Comments and opinions expressed by users do not necessarily reflect the opinions or beliefs of CNA. CNA will not publish comments with abusive language, insults or links to other pages

RESOURCES »

Ads by Google (What's this?)

Featured Videos

#PAUSEforPeace Initiative
#PAUSEforPeace Initiative
Dedicating art to San Juan de la Cruz
A state without territory elects new government
The renewal of the Legionaries of Christ
Presentation of the book "The Pastor"
Synod on the Family October 2014
Preferential option for the poor
God is alive, even in sport
'A forbidden God' named Best Film at the International Catholic Film Festival
Vatican backs a 'Pause for Peace' during World Cup final
The effects of religious violence in Sarajevo 
The origin of Corpus Christi 
Corpus Christi at the Vatican 
Homage to an Indian Cardinal
Train of the Child's Light
New book explaining gestures of the Mass
Encounter between Pope Francis and the Charismatic Renewal in the Spirit Movement.
Religious tensions subside amid Balkan floods
John Paul II Center for Studies on Marriage and Family
Saint John Paul II on cartoon
Jul
29

Liturgical Calendar

July 29, 2014

Saint Martha

All readings:
Today »
This year »

Catholic Daily

Gospel of the Day

Jn 11:19-27

Gospel
Date
07/29/14
07/28/14
07/27/14

Daily Readings


First Reading:: Jer 14: 17-22
Gospel:: Jn 11: 19-27

Saint of the Day

St. Martha »

Saint
Date
07/29/14
07/27/14

Homily of the Day

Jn 11:19-27

Homily
Date
07/29/14
07/28/14
07/27/14

Ads by AdsLiveMedia.com

Ads by AdsLiveMedia.com
     HTML
Text only
Headlines
  

Follow us: